Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Videos|January 11, 2013
A New Arsenal of Drugs Fighting Myeloma
Dr. Paul Richardson discusses promising drugs in the pipeline for the treatment of myeloma and new combination treatments using older drugs.
Advertisement
Dr. Paul Richardson discusses promising drugs in the pipeline for the treatment of myeloma and new combination treatments using older drugs.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
5